Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (31-40 of 221) with videos related to

Pageof 23
Sort By:
Expert Opinion on Emerging Drugs|November 27, 2013
Emerging antiangiogenics for renal cancerCharlotte Domblides, Marine Gross-Goupil, Amandine Quivy, et al.
Expert Opinion on Pharmacotherapy|December 17, 2013
Protein kinase inhibitors in renal cell carcinomaAmaury Daste, Thomas Grellety, Marine Gross-Goupil, et al.
European Urology|April 3, 2021
New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?Florent Peyraud, Mathieu Larroquette, Alain Ravaud, et al.
Bulletin Du Cancer|March 31, 2015
[Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]Christophe Massard, Jean-Jacques Patard, Olivier Hermine, et al.
Brain, Behavior, and Immunity|March 31, 2004
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapyLucile Capuron, Alain Ravaud, Andrew H Miller, et al.
British Journal of Haematology|April 12, 2007
Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemiaMarie-Sarah Dilhuydy, Thomas Jouary, Hélène Demeaux, et al.
Cancer Investigation|May 28, 2010
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practiceManuela Schmidinger, Dirk Arnold, Cezary Szczylik, et al.
Bulletin Du Cancer|January 1, 2019
Laura Salabert, Baptiste Sionneau, Valérie Cochin, et al.
Cancer Treatment Reviews|June 1, 2012
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkersDaniel Castellano, Alain Ravaud, Manuela Schmidinger, et al.
Oral Oncology|May 13, 2019
The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case reportMatthieu Lasserre, Charlotte Domblides, Marine Gross-Goupil, et al.
Pageof 23

Showing results (31-40 of 221) with videos related to

Sort By:
Pageof 23
Expert Opinion on Emerging Drugs|November 27, 2013
Emerging antiangiogenics for renal cancerCharlotte Domblides, Marine Gross-Goupil, Amandine Quivy, et al.
Expert Opinion on Pharmacotherapy|December 17, 2013
Protein kinase inhibitors in renal cell carcinomaAmaury Daste, Thomas Grellety, Marine Gross-Goupil, et al.
European Urology|April 3, 2021
New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?Florent Peyraud, Mathieu Larroquette, Alain Ravaud, et al.
Bulletin Du Cancer|March 31, 2015
[Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]Christophe Massard, Jean-Jacques Patard, Olivier Hermine, et al.
Brain, Behavior, and Immunity|March 31, 2004
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapyLucile Capuron, Alain Ravaud, Andrew H Miller, et al.
British Journal of Haematology|April 12, 2007
Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemiaMarie-Sarah Dilhuydy, Thomas Jouary, Hélène Demeaux, et al.
Cancer Investigation|May 28, 2010
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practiceManuela Schmidinger, Dirk Arnold, Cezary Szczylik, et al.
Bulletin Du Cancer|January 1, 2019
Laura Salabert, Baptiste Sionneau, Valérie Cochin, et al.
Cancer Treatment Reviews|June 1, 2012
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkersDaniel Castellano, Alain Ravaud, Manuela Schmidinger, et al.
Oral Oncology|May 13, 2019
The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case reportMatthieu Lasserre, Charlotte Domblides, Marine Gross-Goupil, et al.
Pageof 23